These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 2787958)

  • 21. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.
    Lip GYH; Lane DA; Buller H; Apostolakis S
    Chest; 2013 Dec; 144(6):1839-1847. PubMed ID: 24009027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
    Arch Intern Med; 1996 Feb; 156(4):409-16. PubMed ID: 8607726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.
    Apostolakis S; Lane DA; Guo Y; Buller H; Lip GY
    J Am Coll Cardiol; 2012 Aug; 60(9):861-7. PubMed ID: 22858389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA
    Denas G; Zoppellaro G; Padayattil Jose S; Antonucci E; Marongiu F; Poli D; Testa S; Tripodi A; Palareti G; Pengo V
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics.
    Fihn SD; Callahan CM; Martin DC; McDonell MB; Henikoff JG; White RH
    Ann Intern Med; 1996 Jun; 124(11):970-9. PubMed ID: 8624064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.
    Carrero JJ; Evans M; Szummer K; Spaak J; Lindhagen L; Edfors R; Stenvinkel P; Jacobson SH; Jernberg T
    JAMA; 2014 Mar; 311(9):919-28. PubMed ID: 24595776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
    Hylek EM; Evans-Molina C; Shea C; Henault LE; Regan S
    Circulation; 2007 May; 115(21):2689-96. PubMed ID: 17515465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.
    Li XS; Deitelzweig S; Keshishian A; Hamilton M; Horblyuk R; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Lip GYH
    Thromb Haemost; 2017 Jun; 117(6):1072-1082. PubMed ID: 28300870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy.
    Fosbol EL; Wang TY; Li S; Piccini J; Lopes RD; Mills RM; Klaskala W; Thomas L; Roe MT; Peterson ED
    Am Heart J; 2013 Nov; 166(5):864-70. PubMed ID: 24176442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
    Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
    Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
    Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
    Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.
    Landefeld CS; Cook EF; Flatley M; Weisberg M; Goldman L
    Am J Med; 1987 Apr; 82(4):703-13. PubMed ID: 3494397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bleeding Risk of Warfarin and Direct Oral Anticoagulants in Younger Population: A Historical Cohort Study Using a Japanese Claims Database.
    Yokoyama S; Tanaka Y; Nakagita K; Hosomi K; Takada M
    Int J Med Sci; 2018; 15(14):1686-1693. PubMed ID: 30588192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study.
    Pengo V; Legnani C; Noventa F; Palareti G;
    Thromb Haemost; 2001 Mar; 85(3):418-22. PubMed ID: 11307807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice.
    An J; Niu F; Lang DT; Jazdzewski KP; Le PT; Rashid N; Meissner B; Mendes R; Dills DG; Aranda G; Bruno A
    J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26187996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.